Press Releases

Daisy Petal™ systems installed in GMP space to enable perfusion fermentation at SIIPL, enabling faster, higher-yield protein production in a compact, user-friendly platform.

Collaboration advances the commercialization of a 10-valent HPV vaccine.

Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.

The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.

Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal™

Daisy Petal™ is now commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.

Recognizing Innovation in Global Life Sciences and Biotechnology HINGHAM, MA, NOVEMBER 19, 2024 ‒ At Sunflower Therapeutics, we’re on a mission to make protein production more accessible, efficient, and cost-effective, and it’s exciting to see our efforts recognized!...

Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.

Grants from the Bill & Melinda Gates Foundation support the optimization of the Dahlia™ small-footprint protein manufacturing system and the de-risking of several protein candidates using Sunflower’s proprietary manufacturing approach.

Sunflower Therapeutics, a public benefit corporation focused on transforming access to biologics medicines for patients worldwide, has delivered its first system for biomanufacturing, the Daisy Petal™ fermentation system.

Roivant Social Ventures (RSV), a not-for-profit social impact organization launched out of Roivant Sciences, today unveiled its executive team and announced its inaugural partnership with Sunflower Therapeutics, a biopharmaceutical company developing simplified manufacturing methods for therapeutic proteins.

Sunflower Therapeutics, a public benefit corporation focused on improving access to biologic medicines for patients worldwide, announced that it was granted a second phase of funding to support an existing award made by the Bill & Melinda Gates Foundation to further the foundation’s charitable purpose of improving global health. This award will support the development of a laboratory-scale, deployable manufacturing system and will culminate in the demonstrated production of a protein subunit for a COVID-19 vaccine candidate later this year.

Sunflower Therapeutics, a public benefit corporation focused on efficient manufacturing for proteins, announced that it has donated $25,000 of its profits earned in 2020 to four non-profit organizations focused on serving the global poor.

Sunflower Therapeutics, a public benefit corporation focused on efficient manufacturing for proteins, announced that it has been awarded a $5.7 million extension of an existing contract with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the purpose of developing a Biologics on Demand (BOD) manufacturing prototype for recombinant protein-based medical countermeasures (MCMs).